Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | MAOA | P21397 | 5/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.82 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | ACHE | P22303 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoxsalen SCHEMBL29376525 | 0.90 | CYP3A4 (1.00) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Methoxsalen SCHEMBL2302069 | 0.90 | CYP3A4 (1.00) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Methoxsalen SCHEMBL19168 | 0.90 | CYP3A4 (1.00) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Methoxsalen SCHEMBL6142553 | 0.89 | CYP3A4 (0.97) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Bergapten SCHEMBL9792363 | 0.88 | CYP3A4 (0.74) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Psoralen SCHEMBL28497870 | 0.84 | KDM4E (0.86) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Methoxsalen SCHEMBL9387169 | 0.84 | CYP3A4 (0.86) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Methoxsalen SCHEMBL10572509 | 0.83 | CYP3A4 (0.84) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Psoralen SCHEMBL2684633 | 0.81 | MAOA (1.00) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 | |
| Psoralen SCHEMBL29503678 | 0.81 | MAOA (1.00) | CYP3A4MAOACYP2D6CYP2A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443922-B1 | The use of apoptotic cells ex vivo to generate regulatory T cells | THERAKOS INC (US) | 2017-05-03 | — | — | EP | claimed |
| EP-1550454-B1 | Extracorporeal photopheresis in combination with anti-TNF treatment | THERAKOS INC (US) | 2011-03-09 | — | — | EP | claimed |
| EP-1469011-B1 | Hemoglobin conjugates | PANZERI EZIO (IT) | 2007-11-07 | — | — | EP | claimed |
| EP-0910428-B1 | PHOTOPHERESIS TREATMENT OF CHRONIC HCV INFECTIONS | THERAKOS INC (US) | 2005-10-26 | — | — | EP | claimed |
| EP-0935462-B1 | PHOTOPHERESIS TREATMENT OF LEUKOCYTES | THERAKOS INC (US) | 2005-07-27 | — | — | EP | claimed |
| EP-0668772-B1 | SPECIFIC IMMUNE SYSTEM MODULATION | UNIV YALE (US) | 2000-08-30 | — | — | EP | claimed |
| EP-0579784-B1 | METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS | ADVANCED RES & TECH INST (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0392429-A1 | Psoralen-reagens | F. HOFFMANN-LA ROCHE AG (CH) | 1990-10-17 | — | — | EP | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-2913052-A1 | Phototherapy compositions and methods | OMJ Ireland Limited (PR) | 2015-09-02 | — | — | EP | disclosed |
| EP-1674095-B1 | Phototherapy compositions | OMJ IRELAND LTD (PR) | 2014-08-20 | — | — | EP | disclosed |
| US-8481008-B2 | Phototherapy compositions and methods | THERAKOS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-0683671-A1 | IMMUNE SYSTEM MODULATION USING PSORALENS ACTIVATED WITH VISIBLE LIGHT | YALE UNIVERSITY (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5462733-A | Irradiating a suspension of cells with visible light in the presence of psoralen | YALE UNIVERSITY (US) | 1995-10-31 | — | — | US | disclosed |
| US-5372929-A | Methods for measuring the inactivation of pathogens | CERUS CORPORATION | 1994-12-13 | — | — | US | disclosed |
| WO-1994017812-A1 | IMMUNE SYSTEM MODULATION USING PSORALENS ACTIVATED WITH VISIBLE LIGHT | YALE UNIVERSITY (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1993015215-A1 | METHODS FOR MEASURING THE INACTIVATION OF PATHOGENS | HRI RESEARCH, INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| US-4464354-A | (3,4-c)-Pyrido psoralens, process of preparation, application in cosmetology and therapeutics, and cosmetological and pharmaceutical composition with them | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | CYP3A4 1067/4885MAOA 1808/4885CYP2D6 1533/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CYP3A4 975/4885MAOA 1886/4885CYP2D6 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.